Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
The inspection closed with the facility receiving an inspection classification of NAI
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Convergent action on AMR identified as an important area of intervention
Subscribe To Our Newsletter & Stay Updated
